Recruiting
Phase 1

Itraconazole & Nacresertib

Sponsor:

AbbVie

Code:

NCT07649954

Conditions

Healthy Volunteer

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Nacresertib

Itraconazole

Study Details

Brief summary:

This study will evaluate how multiple doses of Itraconazole Impacts the performance of Nacresertib in healthy adult participants

The goal of this study is to assess the safety and drug to drug interaction between Itraconazole and Nacresertib.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

Healthy Volunteer

Study ID

NCT07649954

Start date

Jun 23, 2026

Status verified date

Jul, 2026

Completion date

Sep, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Participants must voluntarily sign and date an informed consent, approved by an IEC/IRB, prior to the initiation of any screening or study-specific procedures.
  • Individuals 18 to 65 years of age at the time of screening.
  • Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG.
  • Female participants meet the following criteria.

Non-Childbearing Potential due to meeting at least one of the following criteria:

  • Permanent sterility due to a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Non-surgical permanent infertility due to Mullerian agenesis, androgen insensitivity, or gonadal dysgenesis; investigator discretion should be applied to determining study entry.
  • Postmenopausal female who is age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND a follicle-stimulating hormone (FSH) level ≥ 30 IU/L.
  • Postmenopausal female who is age > 55 years with no menses for 12 or more months without an alternative medical cause.

Exclusion Criteria:

  • History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • Participant has any clinically significant ECG abnormalities including the following:

  • Evidence of 2nd or 3rd degree atrioventricular (AV) block at screening visit or upon initial confinement
  • QT interval corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) ˃ 450 msec (males) or ˃ 460 msec (females) at screening visit or upon initial confinement.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption \[e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.\].
  • Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix.
  • History or evidence of active tuberculosis (TB) disease or latent TB infection.

Study Design

Enrollment

12 participants

Anticipated

Allocation

Non randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Period 1: Nacresertib Only

Participant receives single dose of Nacresertib administered on Day 1

experimental: Period 2: Nacresertib and Itraconazole

Participant will receive itraconazole multiple times on Day 1, followed by a single dose of itraconazole on Days 2 through 11. Participants will also receive a single oral dose of Nacresertib on Day 4.

Interventions

Nacresertib

Oral Tablet

Itraconazole

Oral Capsule

Primary outcome measure

  • Maximum Observed Plasma Concentration (Cmax) of Nacresertib [ Time Frame: Up to Day 12 ]
  • Time to Cmax (Tmax) of Nacresertib [ Time Frame: Up to Day 12 ]
  • Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Nacresertib [ Time Frame: Up to Day 12 ]
  • AUC From Time 0 to the Time Infinity (AUCinf) of Nacresertib [ Time Frame: Up to Day 12 ]
  • Terminal Phase Elimination Rate Constant (Beta) of Nacresertib [ Time Frame: Up to Day 12 ]
  • Terminal Phase Elimination Half-Life (t1/2) of Nacresertib [ Time Frame: Up to Day 12 ]

Central Contacts and Locations

Central contacts

Locations

Acpru /Id# 282339

Recruiting

Grayslake, Illinois, United States, 60030

More Information

Sponsor

AbbVie

Last update posted

Jul 23, 2026

Last verified

Jul, 2026

Keywords

  • Healthy Volunteer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by AbbVie on 2026-07-23.